Category: Hem/Onc News
Highlights From the American Society of Clinical Oncology 2011 Breast Cancer Symposium
September 8–10, 2011 • San Francisco, CA Breast Cancer In Focus Complete abstracts are available in Journal of Clinical Oncology. 2011;29(suppl 27). 275 Albumin-bound paclitaxel (ab-pac) versus […]
October News
Survival Benefits of Platinum-Based Doublet Chemotherapy in Elderly Patients With NSCLC In a multicenter, open-label, randomized phase III trial, Quoix and colleagues compared a carboplatin and […]
Highlights in Sarcoma From the 2011 American Society of Clinical Oncology Meeting
June 3–7, 2011 • Chicago, Illinois Complete abstracts are available in J Clin Oncol. 2011;29 (Suppl). LBA10002 ALETTE: Randomized, Double-Blind, Phase II Trial of Pazopanib Versus Placebo in […]
September News
Crizotinib Approved for Use in ALK-Positive Locally Advanced and Metastatic NSCLC On August 26, the US Food and Drug Administration (FDA) announced its approval of crizotinib […]
August News
Hem/Onc News Benefits of Zoledronic Acid in Early-Stage Breast Cancer Maintained: 62-Month Follow-Up of the ABCSG-12 Trial Results from a 62-month follow-up of the ABCSG-12 (Austrian […]
July News
Hem/Onc News Rituximab as Maintenance Therapy in Elderly Patients With Mantle Cell Lymphoma The first results from the European Mantle Cell Lymphoma (MCL) Network study showed […]
June News
Hem/Onc News A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer Hatzis and colleagues conducted a prospective, multicenter study in order […]
May News
Hem/Onc News Cyclophosphamide, Lenalidomide, and Dexamethasone Improve Survival in Multiple Myeloma In the April 25 issue of the American Journal of Hematology, Kumar and colleagues reported the results […]
April News
FDA Approves Life-Extending Ipilimumab in Metastatic Melanoma Patients On March 25, the US Food and Drug Administration (FDA) approved ipilimumab (Yervoy, Bristol-Myers Squibb) 3 mg/kg to […]
March News
Hem/Onc News FDA Approves Life-Extending Ipilimumab in Metastatic Melanoma Patients On March 25, the US Food and Drug Administration (FDA) approved ipilimumab (Yervoy, Bristol-Myers Squibb) 3 […]
Highlights in Lymphoma From the 2010 American Society of Hematology Meeting
Highlights in Lymphoma From the 2010 American Society of Hematology Meeting December 4–7, 2010 • Orlando, Florida Complete abstracts are available in Blood. 2010;116(21) 114 Final Results From […]
January News
Hem/Onc News First-line Nilotinib and Dasatinib Sustain Advantages Over Imatinib Updates from pivotal phase III trials of the second-generation tyrosine kinase inhibitors dasatinib (Sprycel, Bristol-Myers Squibb) […]
December News
Low Levels of Vitamin D Linked to Cancer Progression and Death in Chronic Lymphocytic Leukemia Patients Vitamin D insufficiency has correlated to inferior prognosis in some cancers. In […]
November News
Afatinib Increases Progression-Free Survival in Patients With Non–Small Cell Lung Cancer Results from 2 clinical trials, LUX-Lung 1 and LUX-Lung 2, examining the investigational compound afatinib […]
October News
Bortezomib Plus Dexamethasone Is Superior to Vincristine, Doxorubicin, and Dexamethasone as Induction Therapy in Newly Diagnosed Multiple Myeloma Results from Intergroupe Francophone du Myélome (IFM) 2005-01, a phase III […]
August News
Sipuleucel-T Extends Survival in Metastatic Prostate Cancer Patients According to study findings reported in the July 29 issue of the New England Journal of Medicine, sipuleucel-T […]
July News
Gefitinib Doubles Progression-free Survival (PFS) in Patients With Non–small-cell Lung Cancer (NSCLC) With Mutated Epidermal Growth Factor Receptor (EGFR) A phase III study conducted in Japan […]
May News
Oral Care Protocol Effective in Patients Receiving Chemotherapy Oral mucositis is a serious side effect of cancer therapy, which results in increased rates of infection and […]
HEM/ONC News
By Ellie Vershvovsky Phase III Study of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma This multicenter, randomized study examined the efficacy,clinical benefit, and safety of 2 […]
BRAF Mutation Is Associated With Worse Survival in Metastatic Colorectal Cancer
HEM/ONC News BRAF Mutation Is Associated With Worse Survival in Metastatic Colorectal Cancer By Ellie Vershvovsky At the 2010 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO […]